LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
APOTEX CORP
Drug class
Pyrimidine Synthesis Inhibitors
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production. Read more about Pyrimidine Synthesis Inhibitors
24 drugs in this class 20 manufacturers
Drugs in Pyrimidine Synthesis Inhibitors
ARAVA (leflunomide)
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
Sanofi-Aventis U.S.
AUBAGIO (teriflunomide)
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
Sanofi-Aventis U.S.
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
ALEMBIC PHARMAC
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
ZYDUS PHARMACEU
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
TEVA PHARM
TERIFLUNOMIDE
MULTIPLE SCLEROSIS AGENTS, GENERAL · RELAPSING FORM OF MULTIPLE SCLEROSIS ·+1
CAMBER PHARMACE
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
BUREL PHARMACEU
LEFLUNOMIDE
ANTIRHEUMATIC AGENTS (DMARDS, NON-BIOLOGIC) · RHEUMATOID ARTHRITIS
AVKARE
Filter & compare in the drug finder →
Opens the drug finder with Pyrimidine Synthesis Inhibitors preselected. Add indication or manufacturer filters there.
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production.
They exert their therapeutic effect primarily by inhibiting dihydroorotate dehydrogenase, a key mitochondrial enzyme essential for generating the pyrimidines required for DNA and RNA synthesis in rapidly proliferating cells.
By arresting lymphocytes in the G1 phase and reducing active T- and B-cell proliferation, these agents suppress targeted immune-mediated inflammatory cascades.
In clinical practice, members of this class—most notably leflunomide and teriflunomide—are primarily indicated for the management of autoimmune disorders, specifically active rheumatoid arthritis and relapsing forms of multiple sclerosis.
-
fda.gov
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production
-
nih.gov
Pyrimidine synthesis inhibitors are an established pharmacologic class of immunomodulatory agents that block de novo pyrimidine nucleotide production They exert their therapeutic effect primarily by inhibiting dihydroorotate dehydrogenase, a key mitochondrial enzyme essential for generating the pyrimidines required for DNA and RNA synthesis in rapidly proliferating cells
-
fda.gov
They exert their therapeutic effect primarily by inhibiting dihydroorotate dehydrogenase, a key mitochondrial enzyme essential for generating the pyrimidines required for DNA and RNA synthesis in rapidly proliferating cells By arresting lymphocytes in the G1 phase and reducing active T- and B-cell proliferation, these agents suppress targeted immune-mediated inflammatory cascades
-
rxce.com
By arresting lymphocytes in the G1 phase and reducing active T- and B-cell proliferation, these agents suppress targeted immune-mediated inflammatory cascades
-
fda.gov
In clinical practice, members of this class—most notably leflunomide and teriflunomide—are primarily indicated for the management of autoimmune disorders, specifically active rheumatoid arthritis and relapsing forms of multiple sclerosis
-
fda.gov
In clinical practice, members of this class—most notably leflunomide and teriflunomide—are primarily indicated for the management of autoimmune disorders, specifically active rheumatoid arthritis and relapsing forms of multiple sclerosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.